Tekla Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Tekla Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-68,150	Closed	-$2.54M	–	201
2021 Q2	$2.54M	Hold	68,150	–	–	0.08%	149
2021 Q1	$1.74M	Hold	68,150	–	–	0.06%	165
2020 Q4	$1.5M	Hold	68,150	–	–	0.05%	169
2020 Q3	$1.23M	Buy	+68,150	New	+$1.41M	0.05%	172
2015 Q1	–	Sell	-156,250	Closed	-$2.57M	–	126
2014 Q4	$2.57M	Buy	+156,250	New	+$1.8M	0.12%	82

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Tekla Capital Management's DRNA Position: Q3 2021 in Review

Tekla Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 68,150 shares — an estimated $2.54M sold.

Tekla Capital Management first reported a position in DRNA in Q4 2014 and held it in 5 quarters. The position peaked at $2.57M in Q4 2014. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Tekla Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Tekla Capital Management sold 68,150 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $2.54M.
Tekla Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2014 and held it in 5 quarters.
Tekla Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $2.57M in Q4 2014.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.